Results 41 to 50 of about 242,514 (346)
Diabetic Medicine, 2022 The use of do‐it‐yourself artificial pancreas systems (DIYAPS) among people with type 1 diabetes is increasing. At present, it is unclear how DIYAPS compares with other technologies such as FreeStyle Libre (FSL) and continuous subcutaneous insulin ...
Rachel Patel +7 more
semanticscholar +1 more source
International Journal of Population Data Science, 2021 Background Evidence is limited on the non-medical factors influencing hospital length of stay (LOS) among paediatric inpatients with diabetes, notably potential social and policy correlates.
Heather Higgins, Neeru Gupta
doaj +1 more source
Optimal Regulation of Blood Glucose Level in Type I Diabetes using Insulin and Glucagon
, 2019 The Glucose-Insulin-Glucagon nonlinear model [1-4] accurately describes how the body responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes.
Della Rossa, Fabio +4 more
core +4 more sources
Effectiveness of Predicted Low-Glucose Suspend Pump Technology in the Prevention of Hypoglycemia in People with Type 1 Diabetes Mellitus: Real-World Data Using DIA:CONN G8 [PDF]
Diabetes & Metabolism JournalWe evaluated the effectiveness of the predictive low-glucose suspend (PLGS) algorithm in the DIA:CONN G8. Forty people with type 1 diabetes mellitus (T1DM) who used a DIA:CONN G8 for at least 2 months with prior experience using pumps without and with ...
Jee Hee Yoo, Ji Yoon Kim, Jae Hyeon Kim
doaj +1 more source
Acute effects of elevated NEFA on vascular function: a comparison of SFA and MUFA [PDF]
, 2010 There is emerging evidence to show that high levels of NEFA contribute to endothelial dysfunction and impaired insulin sensitivity. However, the impact of NEFA composition remains unclear.
Abby K. Thompson +9 more
core +1 more source
Life support systems : the journal of the European Society for Artificial Organs, 1984 The metabolism of insuIin-dependent diabetics (lDDs) cannot always be normalized by the conventional subcutaneous insulin regimen that usually provides only two Injections of reguIar and intermediate-acting insulin per day, but glucose-controlled intravenous insuIin infusion ensures almost normal glycaemia all day long.
Schulz, Gerhard +7 more
openaire +4 more sources
Evolution of Insulin Delivery Devices: From Syringes, Pens, and Pumps to DIY Artificial Pancreas
Diabetes Therapy, 2020 The year 2021 will mark 100 years since the discovery of insulin. Insulin, the first medication to be discovered for diabetes, is still the safest and most potent glucose-lowering therapy.
J. Kesavadev +3 more
semanticscholar +1 more source
Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib
Molecular Oncology, EarlyView.WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute +17 more
wiley +1 more source
Revista de la Sociedad Argentina de Diabetes, 2020 Accompanying the great technological revolution of recent years, insulin infusers have been no exception. From their origins, in just over 50 years, these teams, which changed the lives of many people with diabetes and their families, have experienced ...
Alejandro Daín
doaj +1 more source
Therapeutic strategies for MMAE‐resistant bladder cancer through DPP4 inhibition
Molecular Oncology, EarlyView.We established monomethyl auristatin E (MMAE)‐resistant bladder cancer (BC) cell lines by exposure to progressively increasing concentrations of MMAE in vitro. RNA sequencing showed DPP4 expression was increased in MMAE‐resistant BC cells. Both si‐DPP4 and the DPP4 inhibitor sitagliptin suppressed the viability of MMAE‐resistant BC cells.
Gang Li +10 more
wiley +1 more source